Compare Regeneron Pharmaceuticals Inc (REGN) vs Vanguard Dividend Appreciation Index Fund ETF (VIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $652 (market cap $70.79B), while Vanguard Dividend Appreciation Index Fund ETF trades at $237.46. The key difference: Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Vanguard Dividend Appreciation Index Fund ETF pays none, and Vanguard Dividend Appreciation Index Fund ETF is trading nearer its 52-week high, Regeneron Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| REGN | VIG | |
|---|---|---|
Market Cap | $70.79B | — |
Sector | Health | — |
52-Week High | $812.27 | $239.13 |
52-Week Low | $545.46 | $204.09 |
Enterprise Value | $64.74B | — |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
VIG trades at $236.97, down 0.27% today, with a bullish technical signal from moving averages and oversold RSI_6 at 28.87. Support lies at $235, resistance at $237. The ETF focuses on dividend growth from high-quality U.S. large-caps, with a dividend of $1.00 scheduled for June 2026. Recent news highlights its role in long-term wealth building and diversification away from tech concentration.
Outlook remains positive for income-focused investors seeking stability, though reliance on dividend growth stocks exposes VIG to interest rate sensitivity and economic slowdowns. Its low expense ratio and quality screen support compounding, but yield competition from bonds or higher-dividend ETFs like VYM poses a relative value risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Vanguard Dividend Appreciation Index Fund ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →
